Class / Patent application number | Description | Number of patent applications / Date published |
514100200 | Transporter affecting or utilizing | 52 |
20100279921 | IMPAIRED WOUND HEALING COMPOSITIONS AND TREATMENTS - Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or tissue repair. | 11-04-2010 |
20100298205 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO GASTRIC ACID SECRETION - A method comprising orally administering to a mammal a proton pump inhibitor, or a pharmaceutically acceptable prodrug thereof, and a compound which modulates the activity of the MRP2 or other transporter proteins involved in efflux of a proton pump inhibitor or a prodrug, is disclosed herein, said method being effective for the prevention or treatment of a disease or condition related to gastric acid secretion. This method applied to compounds which both inhibit and stimulate MRP2 activity or activity of other transporter proteins involved in efflux of a proton pump inhibitor or a prodrug. | 11-25-2010 |
20110015117 | METHODS FOR INCREASING ABSORPTION OF PEPTIDES, PEPTIDOMIMETICS AND OTHER GASTROINTESTINAL TRANSPORT PROTEIN SUBSTRATES - Methods and compositions useful for enhancing the absorption and/or transport of peptides, peptidomimetics, and other gastrointestinal transport protein substrates through gastrointestinal transport proteins are provided. The methods comprise using hormones such as 5-methoxy-N-acetyltryptamine to increase the transport of the peptides, peptidomimetics, and substrates. The compositions comprise one or more hormones and one or more peptides, peptidomimetics, and other gastrointestinal transport protein substrates. | 01-20-2011 |
20110028384 | RAP VARIANTS FOR DRUG DELIVERY - The present invention relates to stabilized RAP variants and methods of use thereof. Conjugates of stabilized RAP variants to therapeutic compounds and stabilized RAP fusion proteins comprising therapeutic polypeptides are also presented. | 02-03-2011 |
20110039758 | Molecular Interactions in Neurons - Inhibitors that disrupt binding between a PDZ protein and cognate ligands such as N-methyl-D-aspartate (NMDA) receptors that are involved in various neurological disorders are provided. Pharmaceutical compositions containing such inhibitors and their use in treating neurological diseases such as stroke and ischemia are also disclosed. Screening methods to identify additional inhibitors of specific protein ligand interactions with PDZ proteins are also described. | 02-17-2011 |
20110053829 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS - The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier complex. The present invention also provides methods of application and use of this inventive polymeric carrier and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment such diseases. | 03-03-2011 |
20110086795 | Small peptide modulators of potassium channel trafficking - Provided herein are peptide modulators of ion channels. Specifically, the peptide modulators comprise the amino acid sequence VEDEC wherein V is valine, E is glutamate, D is aspartate, C is cysteine. In certain embodiments, the modulator is attached to the C-terminal end of Slo1 protein isoform. The present invention also claims conjugations of the first valine that make the peptide modulator more membrane permeable, such as myristoyl moieties and arginine-rich cell penetrating peptides. The present invention contemplates use of the peptide modulators in the treatment of diseases/malfunctions such as epilepsy, chronic pain, migraine, asthma, chronic obstructive pulmonary disease, urinary incontinence, hypertension, erectile dysfunction, irritable bowel syndrome, renal disorders of electrolyte imbalance, and possibly in certain kinds of cancer. | 04-14-2011 |
20110098211 | MUTEINS WITH TEAR LIPOCALIN HAVING AFFINITY TO HUMAN C-MET RECEPTOR TYROSINE KINASE AND METHODS FOR OBTAINING THE SAME - The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein. | 04-28-2011 |
20110143991 | Peptides for Activation and Inhibition of Delta-PKC - Peptides able to inhibit or activate the translocation or function of δPKC are identified. Administration of the peptides for protection or enhancement of cell damage due to ischemia is described. Therapeutic methods to reduce damage to cells or to enhance damage to cells due to ischemia are also described, as well as methods for screening test compounds for δPKC-selective agonists and antagonists. | 06-16-2011 |
20110172143 | METHOD OF MODULATING CELL SURVIVAL AND REAGENTS USEFUL FOR SAME - The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75 | 07-14-2011 |
20110172144 | METHODS FOR INCREASING EXPRESSION OF SERCA2A IN CARDIAC MUSCLE - The present invention relates to methods for augmenting SERCA2 mediated calcium ion transport into the sarcoplasmic reticulum of cardiac myocytes of a host. The method includes administering to host cardiac myocytes a zinc finger protein that induces expression of SERCA2a (or administering a nucleic acid molecule encoding such a protein), wherein expression of SERCA2a produces an augmentation in SERCA2 mediated calcium ion transport in treated myocytes, as compared to untreated myocytes. Also provided are methods of treating heart failure by administering to a patient in need thereof, a zinc finger protein or zinc finger protein fused to an effector domain, that induces expression of SERCA2a. | 07-14-2011 |
20110245146 | Non-Viral Delivery of Compounds to Mitochondria - A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which is cleaved within the mitochondrial matrix, and not cleaved within the cellular cytoplasm, of a target cell into which said compound is delivered. Methods of use of such compounds are also described. | 10-06-2011 |
20120010123 | METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASES - A method of treating an LCN13-related condition is provided comprising administering to a patient in need thereof a therapeutically effective amount of a lipocalin or a physiologically active fragment thereof. | 01-12-2012 |
20120021970 | METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION - The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p | 01-26-2012 |
20120172283 | METHODS AND COMPOSITIONS FOR TARGETED DRUG DELIVERY - Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET, MRI or SPECT, and create a biological effect and methods of their use. These DDMs which are variously designed to target specific receptors, internalized and then function biologically, as for purposes of cell destruction or therapy. | 07-05-2012 |
20120172284 | ISOZYME-SPECIFIC ANTAGONISTS OF PROTEIN KINASE C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 07-05-2012 |
20120208742 | Compositions of a peptide targeting system for treating cancer - This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells. | 08-16-2012 |
20120309672 | TREATMENT OF EXTRACELLULAR MATRIX TO REDUCE INFLAMMATION - Pharmaceutical compositions are provided. The compositions comprise a compound comprising the hyaluronan-containing structure A-(low molecular weight hyaluronan domain)-B. The compositions also comprise a pharmaceutically acceptable excipient. A is hydrogen, a substituent that does not comprise a binding site for tumor necrosis factor stimulated gene-6 (“TSG-6”) protein, a substituent that interferes with binding of TSG-6 protein immediately adjacent thereto, or chondroitin. B is hydroxyl, a substituent that does not comprise a binding site for TSG-6 protein, a substituent that interferes with binding of TSG-6 protein immediately adjacent thereto, or chondroitin. The composition is suitable for administration by injection, inhalation, topical rub, or ingestion. Also disclosed are methods and kits for treating a site of inflammation in an individual in need thereof and for decreasing heavy chain modification of pathological hyaluronan at a site of inflammation in an individual in need thereof based on administering the compounds or the compositions. | 12-06-2012 |
20130012426 | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For the Treatment of Psoriasis - This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of Psoriasis. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells. | 01-10-2013 |
20130079273 | CELL GROWTH-PROMOTING PEPTIDE AND USE THEREOF - The pharmaceutical composition includes at least one pharmaceutically acceptable carrier, and an active ingredient including an artificially synthesized peptide includes: (A) an amino acid sequence constituting a cell-penetrating peptide and (B) an amino acid sequence constituting the signal peptide in amyloid precursor protein (APP) or an N-terminal partial amino acid sequence or C-terminal partial amino acid sequence from the amino acid sequence constituting that signal peptide. | 03-28-2013 |
20130172230 | Treating Stroke and Other Diseases Without Inhibiting N-Type Calcium Channels - The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases. | 07-04-2013 |
20130288949 | COMPOSITIONS FOR OXYGEN TRANSPORT COMPRISING A HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN - The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics. | 10-31-2013 |
20130345115 | NUCLEAR PENETRATING H4 TAIL PEPTIDES FOR THE TREATMENT OF DISEASES MEDIATED BY IMPAIRED OR LOSS OF P53 FUNCTION - Methods for using chimeric polypeptides and other compositions comprising H4 tail peptides to increase p53 activity in cells and treat diseases mediated by lack of or dysfunctional p53 function as described. Also provided are chimeric polypeptides and other compositions comprising H4 tail peptides. | 12-26-2013 |
20140038880 | Compositions and Methods for Promoting Wound Healing and Tissue Regeneration - Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject. | 02-06-2014 |
20140045741 | Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease - Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subject's eye. In one aspect, the ocular disease is at least one of diabetic retinopathy, macular degeneration, endopthalmitis, glaucoma, cataracts, ocular herpes. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9). | 02-13-2014 |
20140057828 | Small Peptide Modulators of Potassium Channel Trafficking - Provided herein are methods of improving electrolyte balance across a cell membrane and treating pathophysiological conditions associated with electrolyte imbalance. Improvement or treatment is effected by ontacting the cell or administering a peptide modulator that increases the surface expression of Ca | 02-27-2014 |
20140107013 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1. | 04-17-2014 |
20140287983 | ANTISENSE COMPOSITIONS AND METHODS FOR MODULATING CONTACT HYPERSENSITIVITY OR CONTACT DERMATITIS - Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA. | 09-25-2014 |
20140309157 | WNT FAMILY-DERIVED PEPTIDES AND USE THEREOF - The present invention relates to a WNT-derived novel peptide and use thereof. WNT-derived peptide of the present invention possesses identical or similar activities to natural-occurring WNT protein, and has much higher stability and skin penetration potency than natural-occurring WNT protein. Therefore, the composition containing the present peptide not only shows excellent effects on improvement in hair loss (for example, promotion of hair growth or production of hair), but also has superior efficacies on treatment of a WNT signal transduction pathway-related disorder. In addition, the outstanding activity and stability of the present peptide described above may be greatly advantageous in application to pharmaceutical compositions, quasi-drugs and cosmetics. | 10-16-2014 |
20140315783 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS - The present disclosure provides pyrimidine diol amides of Formula (I), and the pharmaceutically acceptable solvates and prodrugs thereof, wherein A | 10-23-2014 |
20140329737 | Development of Novel Macromolecule Transduction Domain with Improved Cell Permeability and Method for Using Same - The present invention relates to an improved macromolecule transduction domain (MTD), which facilitates permeating the cell membrane of a biologically active molecule, having enhanced cell permeability. Specifically, an improved MTD according to the present invention, compared to an existing MTD, can transmit various types of biologically active molecule from inside the body and inside a test tube more effectively, and thus can be effectively used in a method to genetically alter a biologically active molecule so as to have cell permeability or in a method to transport a biologically active molecule into a cell, or the like. Additionally, the improved MTD can be very useful in development of new drugs and incrementally modified drugs as uses of the improved MTD are possible in drug delivery systems, recombinant protein vaccines or DNA/RNA therapeutic agents, gene or protein therapies, and pharmacologically or medically useful protein production or medical, pharmacological and pharmaceutical compositions. | 11-06-2014 |
20150038401 | CARRIER FOR TARGETING NERVE CELLS - The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by | 02-05-2015 |
20150099690 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF MOLECULES INTO LIVE CELLS - The present disclosure provides methods and compositions related to the cytosolic delivery of proteins and cell-impermeable small molecules into live cells using an endosomolytic dimer of cell-penetrating peptide TAT. | 04-09-2015 |
20150119316 | ANTISENSE COMPOSITION AND METHOD FOR TREATING MUSCLE ATROPHY - A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals. | 04-30-2015 |
20150133362 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION - Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided. | 05-14-2015 |
20150133363 | GLUT-1 AS A RECEPTOR FOR HTLV ENVELOPES AND ITS USES - The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1. | 05-14-2015 |
20150141321 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1. | 05-21-2015 |
20150290335 | BILE ACID OLIGOMER CONJUGATE FOR NOVEL VESICULAR TRANSPORT AND USE THEREOF - The present invention relates to a method for preparing an end site-specific macromolecule-bile acid oligomer conjugate, comprising conjugating a bile acid oligomer which is prepared by oligomerization of two or more bile acid monomers to the terminal site of a macromolecule; a method for body absorption of an end site-specific macromolecule-bile acid oligomer conjugate, comprising administering the macromolecule-bile acid oligomer conjugate prepared by the above method to a subject orally; an end site-specific macromolecule-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of macromolecule; a composition comprising the conjugate; an oral formulation for macromolecule comprising the conjugate, a solubilizer, an excipient, a disintegrant, a binder, and a lubricant; a pharmaceutical composition comprising a heparin-bile acid oligomer conjugate wherein the bile acid oligomer is conjugated to the terminal site of heparin; and a method for treating thrombosis using said composition. | 10-15-2015 |
20150291675 | HUMAN NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (HNGAL) MUTEINS THAT BIND HEPCIDIN AND NUCLEIC ACID ENCODING SUCH - The present invention relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Hepcidin, which proteins preferably are muteins of lipocalin protein. The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such a lipocalin proteins, including uses of these proteins. | 10-15-2015 |
20150299253 | C4S PROTEOGLYCAN SPECIFIC TRANSPORTER MOLECULES - The present invention relates to isolated molecules, peptides, and polypeptides of specific consensus sequences or structures, and to compounds comprising or consisting of such molecules, peptides and polypeptides, which may act as transporter molecules that specifically recognize proteoglycans, in particular, chondroitin-4-sulfate (C4S). The isolated molecules, peptides, polypeptides and compounds of the invention may be conjugated or otherwise linked to a biologically active moiety (BAM). Thus the BAM conjugates allow the specific targeting and delivery of the BAM, which may be, for example, a peptide, chemical entity or nucleic acid, into the cytoplasm and/or nuclei of C4S expressing cells in vitro and in vivo. | 10-22-2015 |
20150299264 | INHIBITION OF CARDIAC FIBROSIS IN MYOCARDIAL INFARCTION - The described invention provides a method for treating myocardial infarction (MI) in a subject comprising administering to the subject a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof made from a fusion between a first polypeptide that is a cell permeable protein (CPP) selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 2), WLRRIKAWLRRIKA (SEQ ID NO: 21), WLRRIKA (SEQ ID NO: 22), YGRKKRRQRRR (SEQ ID NO: 23), FAKLAARLYR (SEQ ID NO: 25), and KAFAKLAARLYR (SEQ ID NO: 26), and a second polypeptide that is a therapeutic domain (TD), and a pharmaceutically acceptable carrier. The described invention also provides a kit comprising a composition comprising at least one MK2 inhibitor peptide; a means for administering the composition; and a packaging material. | 10-22-2015 |
20150307582 | ENGINEERED RECEPTORS AND THEIR USE - Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed. The use of these compositions and nanoparticles, such as for the treatment of pain, cystic fibrosis and asthma, is also disclosed. | 10-29-2015 |
20150315591 | NICKED OR GAPPED NUCLEIC ACID MOLECULES AND USES THEREOF - The present disclosure provides meroduplex (nicked or gapped) ribonucleic acid molecules (mdRNA) that decreases or silences target gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a target gene RNA. In addition, the meroduplex may have one or more modifications or substitutions, such as nucleotide base, sugar, terminal cap structure, internucleotide linkage, or any combination of such modifications. Also provided are methods of decreasing expression of a target gene in a cell or in a subject to treat a disease related to altered expression of a target gene. | 11-05-2015 |
20150352177 | Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease - Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subject's eye. In one aspect, the ocular disease is at least one of diabetic retinopathy, macular degeneration, endopthalmitis, glaucoma, cataracts, ocular herpes. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9). | 12-10-2015 |
20160000864 | PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT HEMOGLOBIN PROTEIN OR SUBUNIT-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT - The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. | 01-07-2016 |
20160017012 | DELIVERY OF CARD PROTEIN AS THERAPY FOR OCCULAR INFLAMMATION - The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. | 01-21-2016 |
20160102120 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers. | 04-14-2016 |
20160151512 | Cell-Penetrating Peptide, Conjugate Comprising Same and Composition Comprising Same | 06-02-2016 |
20160158374 | CELL-PENETRATING PEPTIDE AND CONJUGATE COMPRISING SAME - The present invention relates to a cell-penetrating peptide derived from telomerase, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide according to the present invention. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained. | 06-09-2016 |
20160176937 | SHORT PEPTIDES DERIVED FROM VDAC1, COMPOSITIONS AND METHODS OF USE THEREOF | 06-23-2016 |
20160184447 | CAR Peptide for Homing, Diagnosis & Targeted Therapy for Pulmonary and Fibrotic Disorders - Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal. | 06-30-2016 |
20160186179 | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in Vivo or in Vitro - Compositions and method for down modulating target gene expression which RNA interference, as well as methods for administering said compositions are disclosed. The method comprises administering a first oligonucleotide strand to a cell, incubating the cells for a time period suitable for uptake of the first oligo nucleotide strand prior to administration of a second oligonucleotide strand, wherein the first strand and the second strand form an intracellular duplex which is effective to catalyze degradation of gene target mRNA or inhibit translation of said mRNA. | 06-30-2016 |
20130123178 | GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY - Provided herein are glucagon superfamily peptides conjugated with NHR ligands that are capable of acting at a nuclear hormone receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention. | 05-16-2013 |
20130288967 | MATERIALS AND METHODS FOR CANCER DIAGNOSIS BY EVALUATION OF THE METHYLATION STATUS OF CPG ISLANDS ON CHROMOSOMES 6 AND 8 - Provided are methods, reagents, and kits for evaluating cancer, such as prostate cancer, in a subject. Disclosed methods of evaluating cancer include methods of diagnosing cancer, methods of prognosticating cancer and methods of assessing the efficacy of cancer treatment. The methods include assaying a biological sample for methylation of a CpG island associated with specified genes. Provided reagents and kits include primers suitable for amplifying at least a portion of a target CpG islands associated with specified genes. | 10-31-2013 |
20140024590 | KRAS-Variant And Endometriosis - The invention provides methods for predicting an increased risk or probability of developing endometriosis in a patient based upon the patient's KRAS variant status. | 01-23-2014 |
20140162952 | ERAP1-DERIVED PEPTIDE AND USE THEREOF - Provided is a novel cancer-treating agent which can be used as a novel choice for the treatment of cancer. Specifically provided are: a peptide that inhibits binding of ERAP1 polypeptide to PHB2 polypeptide, which comprises a binding site of the ERAP1 polypeptide to the PHB2 polypeptide, and a pharmaceutical composition comprising the peptide. In addition, provided is a method for screening a drug candidate for treating and/or preventing cancer using inhibition of the binding of the ERAP1 polypeptide to PP1α polypeptide, PKA polypeptide or PKB polypeptide as an index. | 06-12-2014 |
20150065426 | Testosterone Booster Transdermal Compositions - Formulations and methods for transdermal drug delivery compositions that include synergistic combination of three pharmaceutical active ingredients (APIs), such as testosterone, anastrozole, and HCG are disclosed. TBTC of the present disclosure may be indicated for reducing symptoms of testosterone deficiency. Disclosed TBTC may include permeation enhancers that may improve penetration of testosterone, anastrozole, and HCG in human skin. Permeation enhancer compositions within TBTC may include oils from amazon rainforest such as Pracaxi oil, | 03-05-2015 |
20150111825 | OSTEOCALCIN AS A TREATMENT FOR MALE REPRODUCTIVE DISORDERS - Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-1B signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes. | 04-23-2015 |
20160083445 | NOVEL POLYPEPTIDES - The present invention relates to an isolated polypeptide comprising (a) the amino acid sequence set forth in SEQ ID NO: 2; or (b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 2, and to therapeutic treatments based thereon. | 03-24-2016 |
20160106805 | POLYMERIC DELIVERY FORMULATIONS OF LEUPROLIDE WITH IMPROVED EFFICACY - The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate. | 04-21-2016 |